[Familial isolated pituitary adenomas (FIPA). Case report of four families and review of literature.]
CONCLUSIONS: Familial isolated pituitary adenomas are more common than it was previously thought, therefore, specific questioning regarding family history should be a part of the workup of all patients with pituitary adenomas. Genetically induced pituitary tumors often have aggressive behavior in terms of tumor expansion and resistance to different treatment options and often involve a multidisciplinary approach that combines endocrine, neurosurgical, and radiological specialists. PMID: 29022641 [PubMed - as supplied by publisher] (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - October 12, 2017 Category: Endocrinology Authors: Malicka JE, Świrska J, Kurowska M, Dudzińska M, Tarach JS Tags: Endokrynol Pol Source Type: research
Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center
ConclusionIn spite of its relatively straightforward diagnosis, which includes clinical/subclinical hyperthyroidism with or without goiter, increased free thyroxine and nonsuppressed TSH levels, and pituitary mass, the diagnosis of TSH-secreting and cosecreting adenomas was frequently unrecognized and thus much delayed. Serum alpha-subunit levels were high in nearly all patients with TSH-secreting adenomas and useful in excluding other conditions in the differential diagnosis. Proper indication and interpretation of simple laboratory tests should be emphasized in medical education to improve diagnostic accuracy. (Source: J...
Source: Journal of Endocrinological Investigation - October 11, 2017 Category: Endocrinology Source Type: research
Left ventricular twist is impaired in acromegaly: Insights from the three ‐dimensional speckle tracking echocardiographic MAGYAR‐Path Study
Abstract IntroductionAcromegaly is a rare, chronic, disfiguring, and debilitating disease caused, in 90% of cases, by a benign monoclonal growth hormone–secreting pituitary adenoma. The present study aimed to assess left ventricular (LV) rotational and twist mechanics in acromegalic patients and to compare their results to age‐ and gender‐matched healthy controls. MethodsThe present study comprised 24 acromegalic patients, from which 4 were excluded due to insufficient image quality (mean age: 57.8 ± 13.7 years, 7 men). The control group consisted of 18 age‐ and gender‐matched healthy ind...
Source: Journal of Clinical Ultrasound - October 9, 2017 Category: Radiology Authors: Árpád Kormányos, Péter Domsik, Anita Kalapos, Andrea Orosz, Csaba Lengyel, Zsuzsanna Valkusz, Attila Trencsányi, Tamás Forster, Attila Nemes Tags: RESEARCH ARTICLE Source Type: research
The efficacy of medical treatment in patients with acromegaly in clinical practice.
Authors: Young Lee S, Hee Kim J, Hyun Lee J, Hwy Kim Y, Jin Cha H, Wan Kim S, Ha Paek S, Soo Shin C Abstract Although somatostatin analogues (SSAs) are recommended as the first-line medical therapy for acromegaly, dopamine agonists (DAs) are also a therapeutic option for treatment. We aimed to assess and compare the efficacies of DAs and SSAs in treating acromegaly in clinical practice. We included 89 patients with acromegaly who took DAs (bromocriptine [BCT], n = 63; cabergoline [CAB], n = 11) or SSAs (n = 15) as a primary medical therapy for more than 3 months in the Seoul National University Hospital. The CAB (4...
Source: Endocrine Journal - September 23, 2017 Category: Endocrinology Tags: Endocr J Source Type: research
AIP and the somatostatin system in pituitary tumours
Classic somatostatin analogues aimed at somatostatin receptor type 2, such as octreotide and lanreotide, represent the mainstay of medical treatment for acromegaly. These agents have the potential to decrease hormone secretion and reduce tumour size. Patients with a germline mutation in the aryl hydrocarbon receptor-interacting protein gene, AIP, develop young-onset acromegaly, poorly responsive to pharmacological therapy. In this review, we summarise the most recent studies on AIP-related pituitary adenomas, paying special attention to the causes of somatostatin resistance; the somatostatin receptor profile including type...
Source: Journal of Endocrinology - September 22, 2017 Category: Endocrinology Authors: Ibanez-Costa, A., Korbonits, M. Tags: Review Source Type: research
Guidelines versus real life practice: the case of colonoscopy in acromegaly
AbstractPurposeThe aim of this study is to investigate guideline application and colonoscopy findings in real-life practice in acromegaly.MethodsWe conducted a retrospective observational non-interventional and cross-sectional analysis on 146 patients with acromegaly (ACRO) referred to our clinic. We evaluated colonoscopy data, focusing on the correlation between colonoscopy findings and hormonal/metabolic values.ResultsThe total number of colonoscopies performed in ACRO patients increased from 6 in the period 1990 –1994 to 57 in the period 2010–2014. Colonoscopy procedures were performed according to guideline...
Source: Pituitary - September 21, 2017 Category: Endocrinology Source Type: research
[The mouth of patients with acromegaly].
Abstract Orofacial changes are frequent in acromegaly. Their evolution is slowly progressive. The lips (everted and thickened), the mandibular morphology (prognathism), the tongue (macroglossia), the soft palate and the uvula (increased and thickened), the parodontis (gingival hyperplasia, paradontitis), the teeth (increased interdental spaces, hypercementosis, increased dental mobility, multiple tooth loss) are concerned. Functional consequences are significant (obstructive sleep apnea syndrome, malocclusion, pain of the oral maxillofacial area, decrease of the quality of life). They are rarely noticed as the fir...
Source: Presse Medicale - September 21, 2017 Category: General Medicine Authors: Cortet-Rudelli C Tags: Presse Med Source Type: research
Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use
Insulin resistance and the development of diabetes mellitus is a common complication of acromegaly. Prevalence of type 2 diabetes in acromegaly varies from 19 to 56% depending on the case series . In acromegaly, high levels of growth hormone and subsequent stimulation of insulin-like growth factor 1 synthesis contribute to peripheral insulin resistance and the development of diabetes . Although absolute insulin levels may be normal or high, the presence of severe insulin resistance may predispose to diabetic ketoacidosis. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - September 18, 2017 Category: Endocrinology Authors: Jeremy Weiss, Anna J. Wood, Jeffrey D. Zajac, Mathis Grossmann, Sofianos Andrikopoulos, Elif I Ekinci Source Type: research
Body composition and ectopic lipid changes with biochemical control of acromegaly.
Conclusions: Acromegaly is characterized by insulin resistance and hyperinsulinemia but lower IHL, compared to age-, BMI- and sex-matched healthy controls. Biochemical control of acromegaly improves insulin resistance but leads to a less favorable anthropometric phenotype with increased IHL, abdominal adiposity and decreased muscle mass. PMID: 28945897 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 18, 2017 Category: Endocrinology Authors: Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW, Swearingen B, Miller KK Tags: J Clin Endocrinol Metab Source Type: research
Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly
ConclusionThe risk-allele frequencies of studied polymorphisms in acromegaly were higher than in general European population. There is an association betweenFTO gene polymorphisms and HDL cholesterol concentration, suggestingFTO gene polymorphisms may be associated with higher CVD risk in patients with acromegaly. (Source: Pituitary)
Source: Pituitary - September 14, 2017 Category: Endocrinology Source Type: research
Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden
Publication date: 5 December 2017 Source:Molecular and Cellular Endocrinology, Volume 457 Author(s): S. Cannavo, F. Trimarchi, F. Ferraù Increasing evidence suggests that environmental contaminants can exert endocrine disruptors activities and that pollution exposition can have a role in tumorigenic processes. Several environmental pollutants have been shown to affect pituitary cells biology and function. The aryl hydrocarbon receptor (AHR) pathway is involved in xenobiotics' metabolism and in tumorigenesis. A deregulation of the AHR pathway could have a role in pituitary tumours' pathophysiology, especially in the...
Source: Molecular and Cellular Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research
Acromegaly and Cushing's syndrome caused by a neuroendocrine tumor arising within a sacrococcygeal teratoma
Key Clinical Message A 60‐year‐old man with a pre‐existing stable sacrococcygeal teratoma developed acromegaly, ectopic Cushing's syndrome, and 5HIAA secretion. To our knowledge, this represents the first reported case of ACTH and serotonin secretion, and likely GHRH or GH cosecretion, from a sacrococcygeal teratoma in an adult. A 60‐year‐old man with a pre‐existing stable sacrococcygeal teratoma developed acromegaly, ectopic Cushing's syndrome, and 5HIAA secretion. To our knowledge, this represents the first reported case of ACTH and serotonin secretion, and likely GHRH or GH cosecretion, from a sacrococcygea...
Source: Clinical Case Reports - September 14, 2017 Category: General Medicine Authors: Tarig Babiker, Efstathia Kyrodimou, Daniel M. Berney, Mark Gurnell, William M. Drake, Antonia Brooke Tags: Case Report Source Type: research
An unusual airway challenge in a patient with acromegaly
Shivacharan Patel, Jigeeshu V Divatia, Sheila Nainan MyatraJournal of Anaesthesiology Clinical Pharmacology 2017 33(3):410-411 (Source: Journal of Anaesthesiology Clinical Pharmacology)
Source: Journal of Anaesthesiology Clinical Pharmacology - September 11, 2017 Category: Anesthesiology Authors: Shivacharan Patel Jigeeshu V Divatia Sheila Nainan Myatra Source Type: research
Acromegaly and bone.
CONCLUSIONS: In this article, we summarize the pathophysiology, clinical aspects and the new diagnostic tools to better understand bone impairment in acromegaly. PMID: 28880058 [PubMed - as supplied by publisher] (Source: Minerva Endocrinologica)
Source: Minerva Endocrinologica - September 8, 2017 Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
We present a 25‐year‐old man who presented with overgrowth of the right hand associated with occasional pain, numbness, and limited function who was found to have macrodystrophia lipomatosa with fibrolipomatous hamartoma of the median nerve. Reports of this condition are limited in the dermatology literature, and early recognition can lead to better outcomes. (Source: Pediatric Dermatology)
Source: Pediatric Dermatology - September 8, 2017 Category: Dermatology Authors: Tyler Willenbrink, Lindsay Thelin, Gregory Connor, Lucia Diaz Tags: Brief Report Source Type: research
Development of ACRODAT ® , a new software medical device to assess disease activity in patients with acromegaly
ConclusionThe validation study underlined IGF-I and tumor status for routine clinical decision-making, whereas patient-oriented outcome measures received less medical attention. An Acromegaly Disease Activity Tool (ACRODAT) is in development that might assist clinicians towards a more holistic approach to patient management in acromegaly. (Source: Pituitary)
Source: Pituitary - September 8, 2017 Category: Endocrinology Source Type: research
Acromegaly determination using discriminant analysis of the three-dimensional facial classification in Taiwanese.
CONCLUSION: The discriminant functions of detection developed in this study could help patients, their families, medical practitioners and others to identify and track progressive facial change patterns before the possible patients go to the hospital, especially the lateral "angles" which can be calculated by relative point-to-point changes derived from 2D lateral imagery without the 3D anthropometric measurements. This study tries to provide a novel and easy method to detect acromegaly when the patients start to have awareness of abnormal appearance because of facial measurement changes, and it also suggests tha...
Source: Neuroendocrinology Letters - September 7, 2017 Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research
Endoscopic Endo-Nasal Trans-Sphenoidal Excision of Pituitary Tumors: An Institutional Experience
AbstractTo analyze the clinical presentation, management and outcomes of patients with pituitary adenoma treated by Endoscopic Endo-nasal Trans-sphenoidal (EETS) excision. Study was conducted on the basis of medical records of 14 patients who had undergone EETS excision of pituitary adenomas. The data obtained was assessed for demographic and clinical characteristics, radiographic features and post-operative outcomes. Study included 10 males and 4 females. Mean age of patients was 46.43 years (range 16–70 Years). Most common presentation was diminished vision reported in 79% patients. Features of acromegaly enc...
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - September 7, 2017 Category: ENT & OMF Source Type: research
Is there any difference in acromegaly and other chronic disease in quality of life and psychiatric morbidity?
CONCLUSIONS: The psychiatric morbidity, mainly anxiety and insomnia, occurs in 50% of patients with acromegaly. However, the psychological wellbeing and mood seem to be related to other factor such as the acceptance of the illness. Thus, concerning the diagnosis, treatment and monitoring of acromegaly, an interdisciplinary approach, taking into account psychological and psychiatric consultation, is needed. PMID: 28879648 [PubMed - as supplied by publisher] (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - September 7, 2017 Category: Endocrinology Authors: Szcześniak DM, Jawiarczyk-Przybyłowska A, Matusiak Ł, Bolanowska A, Maciaszek J, Siemińska M, Rymaszewska J, Bolanowski M Tags: Endokrynol Pol Source Type: research
Acromegaly treatment in Romania. How close are we to disease control?
Abstract INTRODUCTION: In Romania no nationwide data for acromegaly treatment and control rate are available. Our objective was to assess the acromegaly control rate in a tertiary referral center which covers an important part of Romanian territory and population of patients with acromegaly. MATERIAL AND METHODS: We reviewed the records of all 164 patients (49 males and 115 female; median age 55 (47, 63.5) years) with newly or previously diagnosed acromegaly who have been assessed at least once in our tertiary referral center between January 1st, 2012 and March 31st, 2016. This sample represents 13.6% of the ...
Source: Endokrynologia Polska - September 7, 2017 Category: Endocrinology Authors: Niculescu DA, Baciu IF, Capatina C, Galoiu SA, Gheorghiu ML, Radian S, Trifanescu RA, Caragheorgheopol A, Coculescu M, Poiana C Tags: Endokrynol Pol Source Type: research
Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1 –3): a retrospective cohort study conducted at a single center
This study aimed to investigate preoperative somatostatin analogs (SSAs) treatment on the surgical outcome in patients with acromegaly. (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - September 6, 2017 Category: Endocrinology Authors: Lian Duan, Huijuan Zhu, Bing Xing and Feng Gu Tags: Research article Source Type: research
Endoscopic Transsphenoidal Approach for Acromegaly: Remission Rates in 401 Patients: 2010 Consensus Criteria
Transsphenoidal surgery is the first choice treatment for acromegaly. Postoperative remission is an important predictor of outcome. Various factors have been described as markers of remission preoperative mean growth hormone (GH) and insulin-like growth factor-1 levels, cavernous sinus invasion, tumor size, extra pseudocapsule resection, and experience of the surgeon. (Source: World Neurosurgery)
Source: World Neurosurgery - September 5, 2017 Category: Neurosurgery Authors: Ihsan ANIK, Burak CABUK, Aykut GOKBEL, Alev SELEK, Berrin CETINARSLAN, Yonca ANIK, Savas CEYLAN Tags: Original article Source Type: research
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing ’s disease: a case report
A functional pituitary adenoma can produce multiple anterior-pituitary hormones, such as growth hormone (GH) -producing adenomas (GHoma) with prolactin or thyrotropin stimulating hormone production in the same... (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - September 2, 2017 Category: Endocrinology Authors: Tomoko Takiguchi, Hisashi Koide, Hidekazu Nagano, Akitoshi Nakayama, Masanori Fujimoto, Ai Tamura, Eri Komai, Akina Shiga, Takashi Kono, Seiichiro Higuchi, Ikki Sakuma, Naoko Hashimoto, Sawako Suzuki, Yui Miyabayashi, Norio Ishiwatari, Kentaro Horiguchi & Tags: Case report Source Type: research
Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature.
CONCLUSIONS Reoperative EEA for acromegaly had results similar to those for first-time surgery and rates of control for macroadenomas that were better than historical rates. Cavernous sinus invasion continues to be a negative prognostic indicator for disease control; however, results with EEA show improvement compared with results reported in the prior literature. PMID: 28862548 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery)
Source: Journal of Neurosurgery - September 1, 2017 Category: Neurosurgery Authors: Almeida JP, Ruiz-Treviño AS, Liang B, Omay SB, Shetty SR, Chen YN, Anand VK, Grover K, Christos P, Schwartz TH Tags: J Neurosurg Source Type: research
Response to Letter: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study".
Response to Letter: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study". J Clin Endocrinol Metab. 2017 Sep 01;102(9):3561-3562 Authors: Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu O, Ritchie J, Ioachimescu AG PMID: 28911163 [PubMed - in process] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 1, 2017 Category: Endocrinology Authors: Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu O, Ritchie J, Ioachimescu AG Tags: J Clin Endocrinol Metab Source Type: research
Letter to the Editor: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study".
Letter to the Editor: "Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study". J Clin Endocrinol Metab. 2017 Sep 01;102(9):3560 Authors: Liu SY, Sheng ZF PMID: 28911159 [PubMed - in process] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - September 1, 2017 Category: Endocrinology Authors: Liu SY, Sheng ZF Tags: J Clin Endocrinol Metab Source Type: research
Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes
ConclusionsGH-producing PAs in young patients are intriguing and difficult to treat due to their distinct tumor characteristics, including a lower incidence of the DG subtype and a higher incidence of SS3 adenomas and genetic abnormalities. Therefore, multi-modal therapies are essential to achieve optimal clinical outcomes. (Source: Pituitary)
Source: Pituitary - August 28, 2017 Category: Endocrinology Source Type: research
Pitfalls in early biochemical evaluation after transsphenoidal surgery in patients with acromegaly.
In conclusion, the long-term results can be reliably predicted by the remission criteria early after surgery in most patients with acromegaly. For the accurate evaluation within a year after surgery, however, influence of preoperative treatment with SSA, delayed normalization of IGF-1, and poor GH suppression due to low insulin resistance must be considered, particularly in women. PMID: 28835593 [PubMed - as supplied by publisher] (Source: Endocrine Journal)
Source: Endocrine Journal - August 26, 2017 Category: Endocrinology Tags: Endocr J Source Type: research
The impact of adjustments to the diagnostic criteria for biochemical remission in surgically treated patients with acromegaly.
Abstract BACKGROUND: The suggested criteria for biochemical remission in patients treated for acromegaly were recently modified. The aim of this project was to study to what extent this modification influences remission rates. DESIGN, PATIENTS AND METHODS: This was a retrospective study of 55 consecutive patients [29 men; median age 47years (interquartile range 38-68)] diagnosed with acromegaly between 2003 and 2014. After treatment serum IGF-I and/or GH was measured according to a standardized protocol. The biochemical remission status was defined according to the clinical guidelines from 2010 and2014. ...
Source: Growth Hormone and IGF Research - August 24, 2017 Category: Endocrinology Authors: Kousoula K, Farmaki K, Skoglund T, Olsson DS, Johannsson G, Trimpou P, Ragnarsson O Tags: Growth Horm IGF Res Source Type: research
Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case. PMID: 28824054 [PubMed - as supplied by publisher] (Source: Internal Medicine)
Source: Internal Medicine - August 23, 2017 Category: Internal Medicine Tags: Intern Med Source Type: research
Prevalence of morphometric vertebral fractures in “difficult” patients with acromegaly with different biochemical outcomes after multimodal treatment
ConclusionVertebral fractures are a frequent complication of long-standing active acromegaly. When patients are treated with Pegvisomant, vertebral fractures may occur in close relationship with active acromegaly and coexistent untreated hypogonadism. (Source: Endocrine)
Source: Endocrine - August 23, 2017 Category: Endocrinology Source Type: research
Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database
Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly characteristics over time. The Liège Acromegaly Survey (LAS) Database, a relational database, is designed to assess the profile of acromegaly patients at diagnosis and during long-term follow-up at multiple treatment centers. The following results were obtained at diagnosis. The study population consisted of 3173 acromegaly patients from ten countries; 54.5% were female. Males were significantly younger at diagnosis than females ...
Source: Endocrine-Related Cancer - August 22, 2017 Category: Endocrinology Authors: Petrossians, P., Daly, A. F., Natchev, E., Maione, L., Blijdorp, K., Sahnoun-Fathallah, M., Auriemma, R., Diallo, A. M., Hulting, A.-L., Ferone, D., Hana, V., Filipponi, S., Sievers, C., Nogueira, C., Fajardo-Montanana, C., Carvalho, D., Hana, V., Stalla, Tags: Research Source Type: research
Evidence of dysexecutive syndrome in patients with acromegaly
ConclusionsAcromegalic patients were severely impaired in semantic inhibition, executive processing, working memory and executive inhibition, and they have realized a portion of these deficits. A high level of IGF-1, disease duration may contribute to the impairment of specific aspects of executive function. (Source: Pituitary)
Source: Pituitary - August 19, 2017 Category: Endocrinology Source Type: research
Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly
AbstractBackgroundStudies comparing primary medical treatment of acromegaly with surgery are often non-randomized, and not stratified by illness severity. We prospectively compared primary medical therapy with pituitary surgery in patients with acromegaly. All patients had macroadenomas, at least one random human growth hormone (GH) level ≥12.5 ng/mL, elevated IGF-I levels and failure to suppress GH to
Source: Pituitary - August 19, 2017 Category: Endocrinology Source Type: research
Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats
ConclusionsAP102 is a new dual SSTR2/SSTR5-specific somatostatin analog that acutely reduces growth hormone but does not cause hyperglycemia during acute or chronic administration in a healthy rat model. Further studies in diabetic animals and in humans are necessary to determine the potential utility of AP102 in the clinical setting. (Source: Endocrine)
Source: Endocrine - August 18, 2017 Category: Endocrinology Source Type: research
Delayed Diagnosis of Acromegaly in the Context of Post-Traumatic Stress Disorder due to Symptoms Mimicking Known Psychotropic Medication Side Effects.
CONCLUSION: This case shows that side effects of medications can easily mimic some medical conditions. The possibility of unrecognized disease should not be overlooked simply because a patient's symptoms that develop after starting a medication correspond well the side effect profile of the prescribed medications. This is especially true if side effects do not stop with alteration of medication dose, cessation of the medication, or changing to another medication. Pituitary adenomas are rare in patients treated for PTSD. However, attribution of PTSD patient's symptoms to the side effects of selective serotonin reuptake inhi...
Source: Military Medicine - August 17, 2017 Category: International Medicine & Public Health Tags: Mil Med Source Type: research
Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry
In this study, we examine if the incidence of myocardial infarction (MI) and stroke differ from that of the general population.MethodsData from the German Acromegaly Registry in seven specialized endocrine centres were analysed (n = 479, 56% female, 46 years old at diagnosis, 5549 person-years from diagnosis). Standardized incidence ratios (SIR) were calculated as compared to the general population.ResultsMI and stroke incidences were very close to those of the general population with an SIR (95% CI) of 0.89 (0.47 –1.52, p = 0.80) for MI and 1.17 (0.66–1.93, p =&thi...
Source: Pituitary - August 14, 2017 Category: Endocrinology Source Type: research
Acromegaly is associated with increased cancer risk: a survey in Italy
It is debated if acromegalic patients have an increased risk to develop malignancies. The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era. It was evaluated the incidence of cancer in an Italian nationwide multicenter cohort study of 1512 acromegalic patients, 624 men and 888 women, mean age at diagnosis 45 ± 13 years, followed up for a mean of 10 years (12573 person-years) in respect to the general Italian population. Cancer was diagnosed in 124 patients, 72 wom...
Source: Endocrine-Related Cancer - August 14, 2017 Category: Endocrinology Authors: Terzolo, M., Reimondo, G., Berchialla, P., Ferrante, E., Malchiodi, E., De Marinis, L., Pivonello, R., Grottoli, S., Losa, M., Cannavo, S., Ferone, D., Montini, M., Bondanelli, M., De Menis, E., Martini, C., Puxeddu, E., Velardo, A., Peri, A., Faustini-Fu Tags: Research Source Type: research
Cancers, Vol. 9, Pages 103: Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review
Cancers, Vol. 9, Pages 103: Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review Cancers doi: 10.3390/cancers9080103 Authors: Ryuya Yamanaka Eisuke Abe Toshiteru Sato Azusa Hayano Yasuo Takashima Pituitary adenomas are often treated with radiotherapy for the management of tumor progression or recurrence. Despite the improvement in cure rates, patients treated by radiotherapy are at risk of development of secondary malignancies. We conducted a comprehensive literature review of the secondary intracranial tumors that occurred following radiotherapy to pituitary aden...
Source: Cancers - August 8, 2017 Category: Cancer & Oncology Authors: Ryuya Yamanaka Eisuke Abe Toshiteru Sato Azusa Hayano Yasuo Takashima Tags: Review Source Type: research
Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center
The objective of this study was to examine acromegaly treatment outco... (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - August 4, 2017 Category: Endocrinology Authors: John D. Carmichael, Michael S. Broder, Dasha Cherepanov, Eunice Chang, Adam Mamelak, Qayyim Said, Maureen P. Neary and Vivien Bonert Tags: Research article Source Type: research
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro.
In this study, we compared the effects of pasireotide to those of octreotide in vitro on meningioma primary cell cultures, both alone and in combination with the mTOR inhibitor everolimus. Significant mRNA expression levels of SST1, SST2, and SST5 were observed in 40.5%, 100%, and 35% of meningioma samples, respectively. Pasireotide had a significantly stronger inhibitory effect on cell proliferation than octreotide. The effect of pasireotide, but not of octreotide, was significantly stronger in the group expressing the highest level of SST1 mRNA. Combined treatment with pasireotide and everolimus induced a higher reductio...
Source: Oncotarget - August 3, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature
ConclusionDouble pituitary adenomas are rare but most commonly found with GH- or ACTH-producing tumors. It is critical to remove all identified possible adenomas to achieve biochemical cure and clinicians should have heightened sensitivity in patients with acromegaly or Cushing ’s Disease. (Source: Pituitary)
Source: Pituitary - August 1, 2017 Category: Endocrinology Source Type: research
Craniopharyngioma in a patient with acromegaly due to a pituitary macroadenoma
We present the first reported case of a craniopharyngioma as a second primary tumor in a patient with acromegaly due to a growth hormone (GH)-secreting pituitary adenoma. The patient was lost for follow-up for 18 years after trans-sphenoidal pituitary surgery for a GH-secreting pituitary adenoma. She presented with headaches and decreased visual acuity, and showed unsuppressed GH in an oral glucose load test with high IGF-1 levels. Brain MRI showed a suprasellar cystic mass and the patient underwent surgery for cyst drainage resulting in postoperative improvement in her vision. Biopsy of the mass confirmed the diagnosis of...
Source: Annals of Saudi Medicine - July 27, 2017 Category: General Medicine Tags: ISSUE 6 Source Type: research
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry
AbstractPurposeThis analysis evaluates the 2-year effectiveness and safety of lanreotide depot/autogel (LAN), as well as treatment convenience and acromegaly symptom relief, from the Somatuline® Depot for Acromegaly (SODA) registry, a post-marketing, open-label, observational, multicenter, United States registry study.MethodsPatients with acromegaly treated with LAN were eligible for enrollment. Demographics, LAN dose, extended dosing interval (EDI) (interval of injections ≥42 days), insulin-like growth factor 1 (IGF-1), growth hormone (GH), glycated hemoglobin, adverse events (AEs), injection convenience, and sympt...
Source: Pituitary - July 24, 2017 Category: Endocrinology Source Type: research
Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism
Conclusion: In this review, we aim to provide evidence for the correlation between the two disorders.Integr Med Int 2017;4:94-100 (Source: Integrative Medicine International)
Source: Integrative Medicine International - July 21, 2017 Category: Complementary Medicine Source Type: research
Co-Occurrence of Acromegaly and Hematological Disorders: A Myth or Common Pathogenic Mechanism?
Conclusion: In this review, we aim to provide evidence for the correlation between the two disorders.Integr Med Int 2017;4:94-100 (Source: Integrative Medicine International)
Source: Integrative Medicine International - July 20, 2017 Category: Complementary Medicine Source Type: research
Oldest case of gigantism? Assessment of the alleged remains of Sa-Nakht, king of ancient Egypt
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): Francesco M Galassi, Maciej Henneberg, Wouter de Herder, Frank Rühli, Michael E Habicht (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research
Effects of environmental pollutants on signaling pathways in rat pituitary GH3 adenoma cells.
Abstract An increased rate of acromegaly was reported in industrialized areas, suggesting an involvement of environmental pollutants in the pathogenesis and behavior of GH-secreting pituitary adenomas. Based on these premises, the aim of the study was to evaluate the effects of some widely diffused pollutants (i.e. benzene, BZ; bis(2-ethylhexyl) phthalate, DEHP and polychlorinated biphenyls, PCB) on growth hormone secretion, the somatostatin and estrogenic pathways, viability and proliferation of rat GH-producing pituitary adenoma (GH3) cells. All the pollutants induced a statistically significant increase in GH s...
Source: Environmental Research - July 18, 2017 Category: Environmental Health Authors: Fortunati N, Guaraldi F, Zunino V, Penner F, D'Angelo V, Zenga F, Pecori Giraldi F, Catalano MG, Arvat E Tags: Environ Res Source Type: research
Association between ACE and AGT polymorphism and cardiovascular risk in acromegalic patients
AbstractPurposeWhether the renin –angiotensin–aldosterone system plays a role or not in the development of cardiovascular morbidity in acromegaly patients is unknown. The aim of the study was to investigate the association between ACE (I/D) and AGT (M235T) gene polymorphisms and cardiovascular and metabolic disorders in the acr omegaly.MethodsThe study included one hundred and seventeen acromegalic patients (62 F/55 M, age: 50.2 ± 12.3 years) and 106 healthy controls (92 F/14 M, age: 41.4 ± 11.3 years). PCR method was used to evaluate the prevalence...
Source: Pituitary - July 15, 2017 Category: Endocrinology Source Type: research
Etiology of Hypopituitarism in Adult Patients: The Experience of a Single Center Database in the Serbian Population.
Conclusion. The most common causes of hypopituitarism in our database are pituitary adenomas. Increased awareness of the other causes of pituitary dysfunction, such as congenital, head trauma, extrapituitary cranial irradiation, and infections, is the reason for a higher frequency of these etiologies of hypopituitarism in the presented database. PMID: 28702053 [PubMed] (Source: International Journal of Endocrinology)
Source: International Journal of Endocrinology - July 14, 2017 Category: Endocrinology Tags: Int J Endocrinol Source Type: research